Abstract
Rheumatoid Arthritis, RA, is a common polygenic multi-factorial chronic inflammatory disorder that involves complex interactions between genetic and environmental factors. Despite major advances, the aetiology of the disease is still not completely understood. In this post-genome era, the sequencing of the human and some murine genomes as well as advances in global screening technologies offer an opportunity to accelerate the search for new pathological pathways and to identify new therapeutic targets. Animal models of RA offer an opportunity to dissect the genetic basis of disease in a simplified genome and controlled environment with the aim of identifying new pathological pathways and thus new therapeutic targets. Linkage analysis in the mouse model has identified more than 60 Loci, controlling disease phenotypes, immune response and cytokines. This indicates that gene variations among inbred mice strains affect the disease and that those polymorphic genes could be potential therapeutic targets. However, progress in identification of susceptibility genes in mouse models is slow. The progress is hampered by the complexity of disease as well as the traditional genetic dissection strategies. In this post-genome era, the sequencing of the human and some murine genomes as well as advances in global screening technologies offer an opportunity to accelerate the progress.
Keywords: Rheumatoid Arthritis, differential expression, Collagen Induced Arthritis, Quantitative Trait Loci, Microarrays, Genomics, Epistasis
Current Pharmaceutical Design
Title: Dissecting the Genetic Basis of Rheumatoid Arthritis in Mouse Models
Volume: 12 Issue: 29
Author(s): Saleh M. Ibrahim and Xinhua Yu
Affiliation:
Keywords: Rheumatoid Arthritis, differential expression, Collagen Induced Arthritis, Quantitative Trait Loci, Microarrays, Genomics, Epistasis
Abstract: Rheumatoid Arthritis, RA, is a common polygenic multi-factorial chronic inflammatory disorder that involves complex interactions between genetic and environmental factors. Despite major advances, the aetiology of the disease is still not completely understood. In this post-genome era, the sequencing of the human and some murine genomes as well as advances in global screening technologies offer an opportunity to accelerate the search for new pathological pathways and to identify new therapeutic targets. Animal models of RA offer an opportunity to dissect the genetic basis of disease in a simplified genome and controlled environment with the aim of identifying new pathological pathways and thus new therapeutic targets. Linkage analysis in the mouse model has identified more than 60 Loci, controlling disease phenotypes, immune response and cytokines. This indicates that gene variations among inbred mice strains affect the disease and that those polymorphic genes could be potential therapeutic targets. However, progress in identification of susceptibility genes in mouse models is slow. The progress is hampered by the complexity of disease as well as the traditional genetic dissection strategies. In this post-genome era, the sequencing of the human and some murine genomes as well as advances in global screening technologies offer an opportunity to accelerate the progress.
Export Options
About this article
Cite this article as:
Ibrahim Saleh M. and Yu Xinhua, Dissecting the Genetic Basis of Rheumatoid Arthritis in Mouse Models, Current Pharmaceutical Design 2006; 12 (29) . https://dx.doi.org/10.2174/138161206778559731
DOI https://dx.doi.org/10.2174/138161206778559731 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Molecular Imaging Aided Improvement in Drug Discovery and Development
Current Biotechnology Micro- and Macrovascular Treatment Targets in Scleroderma Heart Disease
Current Pharmaceutical Design Cardiovascular disease management through restrained inflammatory responses
Current Pharmaceutical Design Human Papilloma Virus Vaccine Associated Uveitis
Current Drug Safety Emerging Roles of MicroRNA-22 in Human Disease and Normal Physiology
Current Molecular Medicine Mechanisms of Herb-Induced Nephrotoxicity
Current Medicinal Chemistry Recent Knowledge and New Pharmaceutical Products in Potential Alleviation of Endometriosis
Recent Patents on Inflammation & Allergy Drug Discovery Beneficial Effects of Traditional Chinese Medicine on the Treatment of Osteoporosis on Ovariectomised Rat Models
Current Drug Targets Drug Induced Cutaneous Manifestations due to Treatment of Gastrointestinal Disorders
Current Drug Metabolism Aberrant Activation of Arachidonic Acid and Eicosanoid Pathways-Targets for Treating Prostate Cancer
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Management of Spondyloarthropathy in Asian Countries
Current Rheumatology Reviews Pharmacotherapy of Abdominal Aortic Aneurysms
Current Vascular Pharmacology Interrelationship Between Periapical Lesion and Systemic Metabolic Disorders
Current Pharmaceutical Design Therapeutic Agents Against COVID-19 with Clinical Evidence
Current Pharmaceutical Design Recent Patents in Plant Biotechnology: Impact on Global Health
Recent Patents on Biotechnology Cytotoxic T Lymphocyte Antigen 4 Gene +49 A/G (rs231775) Polymorphism and Susceptibility to Systemic Lupus Erythematosus
Current Rheumatology Reviews Pleuroparenchymal Fibroelastosis: Associations and Underlying Conditions
Current Respiratory Medicine Reviews Current Status of Complementary and Alternative Medicine in the Treatment of Rheumatic Disease Pain
Current Rheumatology Reviews Lysophospholipids: Their Generation, Physiological Role and Detection. Are They Important Disease Markers?
Mini-Reviews in Medicinal Chemistry Therapeutic Approaches to Chronic Intestinal Inflammation by Specific Targeting of Mucosal IL-7 / IL-7R Signal Pathway
Current Drug Targets - Inflammation & Allergy